Project Grant HT94252510254
Award Date
4/15/25
Completion Date
4/14/27
Dollars Obligated
$778K
Federal Agency
Defense Health Agency
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
Boston, MA 02215, USA
Similar Awards
The Defense Health Agency awarded Dana-Farber Cancer Institute a $1,046,135 project grant under the Military Medical Research and Development program to conduct research titled "Drugging the Undruggable: Programming Ovarian Cancer Cells as the Next-Generation Immunotherapy." The three-year award runs from May 15, 2023 to May 14, 2026. As the prime recipient, Dana-Farber will leverage its expertise in tumor biology, immunology and drug development to research new therapies for ovarian...
The Defense Health Agency awarded a $784,602 Project Grant to Dana-Farber Cancer Institute, Inc. (doing business as Dfci) under the Military Medical Research and Development program (CFDA 12.420). The grant will support research from January 2023 to January 2026 to develop next-generation immunotherapy for breast cancer by turning breast cancer cells against themselves. The Military Medical Research and Development program aims to transform military and public health through innovative medical...
The federal Project Grant award in the amount of $3,291,419.00 was provided by the Defense Health Agency (DHA), which administers the Military Medical Research and Development (CFDA 12.420) federal grant program. The award supports a Phase 1 clinical trial using autologous, MUC1-activated T cells expanded from peripheral blood to treat patients with relapsed and resistant ovarian cancer. This research project, conducted by Mayo Clinic Arizona, aims to explore innovative immunotherapy...
This federal Project Grant award from the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program provides $1,229,700.00 to the Dana-Farber Cancer Institute, Inc. (DFCI) to support research on the molecular associations of response to neoadjuvant antiandrogen therapies in high-risk localized prostate cancer. The award, which runs from August 15, 2024 to August 14, 2028, will enable DFCI, a leading cancer research institution, to conduct advanced biomedical...
The Defense Health Agency (DHA) awarded Dana-Farber Cancer Institute, Inc. (DFCI) a $4,991,950 Project Grant under the Military Medical Research and Development (CFDA 12.420) federal grant program. The grant, awarded on November 1, 2024, will fund an investigation of a multi-cancer early detection test in a high-risk military population. The project aims to advance medical research and improve healthcare for military service members and the broader public. DFCI, a prestigious non-profit cancer...
This Project Grant award from the Defense Health Agency provides $979,875 to Dana-Farber Cancer Institute, Inc. for research under the Military Medical Research and Development program. The award aims to further optimize dual-targeted CAR T cells to achieve cures for advanced clear cell renal cell carcinoma (CCRCC) by fine-tuning CAR constructs against carbonic anhydrase IX and CD70 antigens based on tumor expression levels. Brigham and Women's Hospital, Inc. will receive a sub-award to...
The Department of the Army Medical Command awarded a $1,039,740 project grant to Dana-Farber Cancer Institute, Inc. (doing business as Dfci) to support research titled "NOVEL SYNERGISTIC ATR INHIBITOR COMBINATIONS FOR OVARIAN CANCER THERAPY." The period of performance is from August 1, 2021 to July 31, 2025. This project grant was awarded under the Military Medical Research and Development program (CFDA 12.420). This program supports basic, applied, and advanced biomedical research...
The U.S. Defense Health Agency has awarded a $712,000 Project Grant through the Military Medical Research and Development program (CFDA 12.420) to the Dana-Farber Cancer Institute, Inc. (doing business as Dfci) in Boston, MA. The 2-year grant, with a period of performance from July 1, 2024 to June 30, 2026, will support a longitudinal study to identify mechanisms of treatment resistance in rhabdomyosarcoma through circulating tumor DNA analysis. As a not-for-profit hospital and cancer research...
The federal Project Grant award of $954,000.00 from the Defense Health Agency was issued to the Massachusetts Institute of Technology (MIT) on May 1, 2025 under the Military Medical Research and Development (CFDA 12.420) federal grant program. The funding supports MIT's research on "TUMOR-TARGETED NANOCARRIERS FOR EFFECTIVE IMMUNOMODULATION OF OVARIAN CANCER", with a performance period running through April 30, 2028. This award aligns with the program's goal of transforming...
The Defense Health Agency has awarded a $4,954,747 Project Grant to the Dana-Farber Cancer Institute, Inc. (doing business as Dfci) to conduct research under the Military Medical Research and Development program (CFDA 12.420). The grant, titled "Novel Immunologic Discovery Platforms to Prevent Metastasis and Recurrence in Breast Cancer," will fund a four-year research project focused on developing new immunology-based approaches to prevent the spread and return of breast cancer. As a...